DK1622639T3 - INTRAVENOUS INJECTION OF NON-NEUROTOXIC PLASMINOGEN ACTIVATORS FOR TREATMENT OF CASES - Google Patents

INTRAVENOUS INJECTION OF NON-NEUROTOXIC PLASMINOGEN ACTIVATORS FOR TREATMENT OF CASES

Info

Publication number
DK1622639T3
DK1622639T3 DK04730516.4T DK04730516T DK1622639T3 DK 1622639 T3 DK1622639 T3 DK 1622639T3 DK 04730516 T DK04730516 T DK 04730516T DK 1622639 T3 DK1622639 T3 DK 1622639T3
Authority
DK
Denmark
Prior art keywords
cases
treatment
intravenous injection
plasminogen activators
neurotoxic plasminogen
Prior art date
Application number
DK04730516.4T
Other languages
Danish (da)
Inventor
Mariola Soehngen
Wolfgang Soehngen
Wolf-Dieter Schleuning
Robert Medcalf
Original Assignee
Lundbeck H As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck H As filed Critical Lundbeck H As
Priority claimed from PCT/EP2004/004626 external-priority patent/WO2004096268A2/en
Application granted granted Critical
Publication of DK1622639T3 publication Critical patent/DK1622639T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK04730516.4T 2003-05-02 2004-04-30 INTRAVENOUS INJECTION OF NON-NEUROTOXIC PLASMINOGEN ACTIVATORS FOR TREATMENT OF CASES DK1622639T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2003/004608 2003-05-02
PCT/EP2003/004729 WO2004096267A1 (en) 2003-05-02 2003-05-06 Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
PCT/EP2004/004626 WO2004096268A2 (en) 2003-05-02 2004-04-30 Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke

Publications (1)

Publication Number Publication Date
DK1622639T3 true DK1622639T3 (en) 2013-04-15

Family

ID=33395696

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04730516.4T DK1622639T3 (en) 2003-05-02 2004-04-30 INTRAVENOUS INJECTION OF NON-NEUROTOXIC PLASMINOGEN ACTIVATORS FOR TREATMENT OF CASES

Country Status (14)

Country Link
JP (1) JP2012077090A (en)
CN (1) CN1849133B (en)
AU (3) AU2003227721A1 (en)
CY (1) CY1114254T1 (en)
DK (1) DK1622639T3 (en)
EA (2) EA013837B1 (en)
ES (1) ES2401782T3 (en)
HK (1) HK1092045A1 (en)
IL (1) IL171636A (en)
MY (1) MY151447A (en)
PT (1) PT1622639E (en)
SI (1) SI1622639T1 (en)
WO (1) WO2004096267A1 (en)
ZA (2) ZA200509053B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (en) 2001-11-02 2003-05-22 Paion Gmbh DSPA for the treatment of stroke
TWI445540B (en) 2007-04-20 2014-07-21 Ajinomoto Kk Anti-hypothermia composition
AR067345A1 (en) * 2007-07-10 2009-10-07 Paion Deutschland Gmbh USE OF THROMBOMODULIN FOR THE PREPARATION OF A THROMBOLITIC MEDICINAL PRODUCT
EP2014296A1 (en) * 2007-07-10 2009-01-14 PAION Deutschland GmbH Novel strategies for increasing the reperfusion in obstructed blood vessel

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE69054B1 (en) * 1988-07-20 1996-08-07 Schering Ag Vampire bat salivary plasminogen activators
NL8902454A (en) * 1989-10-03 1991-05-01 Stichting Centraal Lab MUTANTS OF THE HUMANE PLASMINOGENIC ACTIVATOR INHIBITOR 1 (PAI-1), THEIR PREPARATION AND USE, AND RECOMBINANT POLYNUCLEOTIDES INCLUDING GENETIC INFORMATION CODING FOR THESE MUTANTS.
ES2121817T3 (en) * 1991-09-05 1998-12-16 Schering Ag INHIBITOR OF THE PLATELET AGGREGATION INDUCED BY COLLAGEN.
DE10153601A1 (en) * 2001-11-02 2003-05-22 Paion Gmbh DSPA for the treatment of stroke

Also Published As

Publication number Publication date
AU2010200718A1 (en) 2010-03-18
SI1622639T1 (en) 2013-05-31
ES2401782T3 (en) 2013-04-24
EA201000501A1 (en) 2010-10-29
ZA200703704B (en) 2008-08-27
CN1849133A (en) 2006-10-18
PT1622639E (en) 2013-04-01
WO2004096267A1 (en) 2004-11-11
EA200501733A1 (en) 2006-06-30
CY1114254T1 (en) 2016-08-31
CN1849133B (en) 2011-03-30
JP2012077090A (en) 2012-04-19
AU2003227721A1 (en) 2004-11-23
MY151447A (en) 2014-05-30
AU2004233601B2 (en) 2009-11-26
HK1092045A1 (en) 2007-02-02
AU2004233601A1 (en) 2004-11-11
EA013837B1 (en) 2010-08-30
IL171636A (en) 2013-07-31
ZA200509053B (en) 2007-11-28

Similar Documents

Publication Publication Date Title
NO20055692D0 (en) Intravenous injection of non-neurotoxic plasminogen activators for the treatment of cerebral stroke
NO20042172L (en) Insulin molecule with extended duration of action
DK1567152T3 (en) USE OF RASAGILIN WITH RILUZOL FOR TREATMENT OF AMYOTROPH LATERAL SCLEROSIS
DE60325190D1 (en) MAGNETICALLY IMPROVED INJECTION CATHETER
DK1455782T3 (en) Highly concentrated stable meloxicam solutions for injection without needles
ATE419270T1 (en) MACROCYCLIC INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS WITH NITROGEN-CONTAINING CYCLIC P2 GROUPS
DK1333152T3 (en) Encapsulated fluid for treating boreholes
DK1663287T3 (en) Use of modified cyclosporins for the treatment of HCV diseases
DK1678185T3 (en) 2,3-dihydro-6-nitroimidazo [2,1-b] oxazole compounds for the treatment of tuberculosis
ATE497505T1 (en) MACROCYCLIC INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS
FI20060154A (en) Treatment of neurogenerative conditions
IS8275A (en) Piperazine derivatives for the treatment of HIV infections
IL177544A0 (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
EP1590442A4 (en) Macrocyclic hepatitis c serine protease inhibitors
ATE461209T1 (en) HCV NS-3 SERINE PROTEASE INHIBITORS
IS8142A (en) Medication useful for the treatment of pain
DK1765391T3 (en) BACTERIAL PREPARATIONS FOR THE TREATMENT OF CANCER
DK1803718T3 (en) 4-Tetrazolyl-4-phenylpiperidine derivatives for the treatment of pain
DK1353694T3 (en) Combinations of ezetimibe with aspirin for the treatment of vascular conditions
DE60212066D1 (en) SUPPLY SYRINGE
DK3332789T3 (en) CLADRIBINCUR FOR THE TREATMENT OF MULTIPLE SCLEROSIS
DK1458438T3 (en) DEVICE FOR INJECTION OF PHARMACEUTICALS
DE602004015504D1 (en) OF INJECTION PREPARATIONS
DK1727801T3 (en) Piperazines useful for the treatment of pain
DK1622639T3 (en) INTRAVENOUS INJECTION OF NON-NEUROTOXIC PLASMINOGEN ACTIVATORS FOR TREATMENT OF CASES